Literature DB >> 3264312

H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma.

M I Nishimura1, I Stroynowski, L Hood, S Ostrand-Rosenberg.   

Abstract

Recent reports suggested a correlation between decreased expression of tumor cell MHC class I Ag and increased susceptibility to NK cells. These studies led to the hypothesis that tumor cells displaying reduced levels of MHC class I Ag have reduced tumorigenicity in vivo because they are eliminated from the host by endogenous NK cells. The present studies use the murine hepatoma BW7756 and a spontaneous H-2Kb loss variant, Hepa-1, to test this hypothesis. The parental BW7756 tumor is highly malignant in syngeneic C57L/J hosts while Hepa-1 cells do not give rise to tumors, suggesting that the loss of H-2Kb Ag expression correlates with decreased tumorigenicity and NK susceptibility. Hepa-1 cells were therefore transfected with an H-2Kb gene to generate H-2Kb Ag expressing clones. The resulting clones were tested for tumorigenicity. Syngeneic or NK-deficient C57BL/6-beige/beige mice challenged with Hepa-1 or the H-2Kb transfectants rejected the cells, suggesting that reexpression of H-2Kb Ag does not restore tumorigenicity and that NK cells are not involved in Hepa-1 rejection. In vitro H-2Kb Ag-negative and -positive Hepa-1 cells are equally susceptible to tilorone-boosted NK cells, indicating that MHC class I Ag expression also does not affect in vitro NK susceptibility. Tumor challenged athymic nude and sublethally irradiated syngeneic mice develop tumors demonstrating that T cells are probably responsible for rejection of the Hepa-1 tumor, and that H-2Kb Ag expression has no effect on rejection. Inasmuch as the expression of H-2Kb Ag on Hepa-1 cells does not effect tumorigenicity or in vitro NK susceptibility, the previously reported association between reduced MHC class I Ag levels and increased NK susceptibility is not universally applicable.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264312

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Histocompatibility antigens and natural killer susceptibility.

Authors:  J Peña; R Solana
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 2.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

3.  Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2.

Authors:  W J Storkus; R D Salter; J Alexander; F E Ward; R E Ruiz; P Cresswell; J R Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

4.  The effect of transfected MHC class I genes on sensitivity to natural killer cells.

Authors:  M Holscher; A L Givan; C G Brooks
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

5.  Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo.

Authors:  A Cerwenka; J L Baron; L L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

6.  Tumorigenicity and H-2 expression of papillomavirus-transformed mouse cell lines.

Authors:  A Laatikainen; H Karjalainen; H Jägerroos; H Sarkkinen; R Mäntyjärvi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Cloning and functional characteristics of murine large granular lymphocyte-1: a member of the Ly-49 gene family (Ly-49G2)

Authors:  L H Mason; J R Ortaldo; H A Young; V Kumar; M Bennett; S K Anderson
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

Review 8.  Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control.

Authors:  Megan M Tu; Ahmad Bakur Mahmoud; Andrew P Makrigiannis
Journal:  Front Immunol       Date:  2016-05-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.